Natalie Brajanovski

1.1k total citations · 1 hit paper
11 papers, 500 citations indexed

About

Natalie Brajanovski is a scholar working on Molecular Biology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Natalie Brajanovski has authored 11 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 4 papers in Hematology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Natalie Brajanovski's work include Ubiquitin and proteasome pathways (4 papers), Cancer therapeutics and mechanisms (3 papers) and Acute Myeloid Leukemia Research (2 papers). Natalie Brajanovski is often cited by papers focused on Ubiquitin and proteasome pathways (4 papers), Cancer therapeutics and mechanisms (3 papers) and Acute Myeloid Leukemia Research (2 papers). Natalie Brajanovski collaborates with scholars based in Australia, Taiwan and United States. Natalie Brajanovski's co-authors include Elaine Sanij, Richard B. Pearson, Jiachen Xuan, Keefe T. Chan, Jian Kang, Ross D. Hannan, Grant A. McArthur, Gretchen Poortinga, Donald P. Cameron and Karen E. Sheppard and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Natalie Brajanovski

11 papers receiving 499 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

2021 214 citations Jian Kang, Natalie Brajanovski et al. Signal Transduction and Targeted Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Natalie Brajanovski Australia	7	406	124	64	51	29	11	500
Ioanna Mavrommati United Kingdom	8	307 0.8×	131 1.1×	61 1.0×	47 0.9×	22 0.8×	9	436
Xingling Zheng China	9	322 0.8×	89 0.7×	95 1.5×	38 0.7×	23 0.8×	12	431
Lucia García-Gutiérrez Spain	9	305 0.8×	132 1.1×	62 1.0×	27 0.5×	45 1.6×	15	417
Yann Duchartre United States	5	369 0.9×	94 0.8×	107 1.7×	48 0.9×	40 1.4×	7	467
Anqun Tang China	5	243 0.6×	143 1.2×	50 0.8×	43 0.8×	25 0.9×	6	361
Leslie H. Brail United States	8	294 0.7×	85 0.7×	45 0.7×	45 0.9×	43 1.5×	16	385
Eri Asano Japan	15	375 0.9×	100 0.8×	86 1.3×	40 0.8×	40 1.4×	18	510
Mohammad Ahmad United States	11	237 0.6×	141 1.1×	116 1.8×	35 0.7×	21 0.7×	19	348
Nicole Kiweler Germany	10	290 0.7×	87 0.7×	71 1.1×	26 0.5×	14 0.5×	13	352
Zhi-Ren Liu United States	9	516 1.3×	159 1.3×	96 1.5×	57 1.1×	31 1.1×	9	641

Countries citing papers authored by Natalie Brajanovski

Since Specialization

Citations

This map shows the geographic impact of Natalie Brajanovski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natalie Brajanovski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natalie Brajanovski more than expected).

Fields of papers citing papers by Natalie Brajanovski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natalie Brajanovski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natalie Brajanovski. The network helps show where Natalie Brajanovski may publish in the future.

Co-authorship network of co-authors of Natalie Brajanovski

This figure shows the co-authorship network connecting the top 25 collaborators of Natalie Brajanovski. A scholar is included among the top collaborators of Natalie Brajanovski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natalie Brajanovski. Natalie Brajanovski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Behrens, Kira, Natalie Brajanovski, Zhen Xu, et al.. (2024). ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia. Science Advances. 10(10). eadj8803–eadj8803. 6 indexed citations

Maclachlan, Kylee, Jian Kang, Andrew Cuddihy, et al.. (2024). Targeting the ribosome to treat multiple myeloma. SHILAP Revista de lepidopterología. 32(1). 200771–200771. 6 indexed citations

Kang, Jian, Natalie Brajanovski, Keefe T. Chan, et al.. (2021). Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduction and Targeted Therapy. 6(1). 323–323. 214 indexed citations breakdown →

Xuan, Jiachen, et al.. (2021). Harnessing the Nucleolar DNA Damage Response in Cancer Therapy. Genes. 12(8). 1156–1156. 13 indexed citations

Yan, Shunfei, Jiachen Xuan, Natalie Brajanovski, et al.. (2020). The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. British Journal of Cancer. 124(3). 616–627. 29 indexed citations

Khot, Amit, Natalie Brajanovski, Donald P. Cameron, et al.. (2019). First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. Cancer Discovery. 9(8). 1036–1049. 132 indexed citations

Diesch, Jeannine, Megan J. Bywater, Elaine Sanij, et al.. (2019). Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation. Communications Biology. 2(1). 39–39. 32 indexed citations

Khot, Amit, Natalie Brajanovski, Donald P. Cameron, et al.. (2017). RNA Polymerase 1 Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Malignancies: Results of a Phase I First in Human Study. Blood. 130. 3835–3835. 2 indexed citations

Martin, Claire, Carleen Cullinane, Laura Kirby, et al.. (2017). Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. International Journal of Cancer. 142(10). 2139–2152. 54 indexed citations

10.

Khot, Amit, Natalie Brajanovski, Donald P. Cameron, et al.. (2015). A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of a first in class Pol1 inhibitor (CX-5461) in Patients with Advanced Haematologic Malignancies (HM). Clinical Lymphoma Myeloma & Leukemia. 15. e280–e281. 2 indexed citations

11.

Harrison, Simon J., Amit Khot, Natalie Brajanovski, et al.. (2015). A phase 1, open-label, dose escalation, safety, PK and PD study of a first in class Pol1 inhibitor (CX-5461) in patients with advanced hematologic malignancies (HM).. Journal of Clinical Oncology. 33(15_suppl). e22212–e22212. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact